Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study
银屑病患者在强制非医疗原因转换至生物类似药 SB5 和 GP2017 后,其真实世界药物生存率的比较:一项全国性队列研究
期刊:Acta Dermato-Venereologica
影响因子:3.7
doi:10.2340/actadv.v105.42572
Sieborg, Johan; Maul, Julia-Tatjana; Wu, Jashin J; Loft, Nikolai Nguyen; Skov, Lone; Bryld, Lars Erik; Rasmussen, Mads Kirchheiner; Dam, Tomas Norman; Bertelsen, Trine; Ajgeiy, Kawa Khaled; Thomsen, Simon Francis; Thyssen, Jacob P; Egeberg, Alexander; Thein, David